Navigation Links
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Date:3/7/2012

is a pre-IND biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham, Michael Kauffman, Giulio Draetta and Ronald DePinho in 2008.  Karyopharm has raised approximately $34M since its inception. The Company has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. By inhibiting the nuclear export of tumor suppressor proteins (TSP), Karyopharm's drug candidates force the activation of the cell's key TSP and anti-inflammatory pathways including p53, p21, pRB, FoxO, and IkB, the body's inhibitor of nuclear factor NF-kB.  Karyopharm anticipates entering the clinic this year with its first oral SINE compound for the treatment of various cancers in humans, and has already begun studies of SINE in canine cancers, particularly lymphoma, one of the most common dog tumors. The Company is also evaluating the use of SINEs in autoimmune, viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.

CONTACT: Michael Kauffman, mkauffman@karyopharm.com, +1-508-975-4821

 


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
5. Orexigen Therapeutics to Present at Upcoming Conferences
6. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 SPIE Fellow Glenn Boreman, Professor ... Science and Director of the Center for Optoelectronics and ... Charlotte, and co-founder and Chairman of the Board of ... 2015 Vice President of SPIE, the international society for ... announced recent election results at the Annual General Meeting ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
(Date:8/28/2014)... Exciting new work by a Florida State University research ... can take your temperature, emit white light, and convert ... molecule looks like a butterfly. , Biwu Ma, associate ... in the FAMU-FSU College of Engineering, created the molecule ... continued to discover that his creation has many other ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... Curb Unsafe Sex and Drug, Use are ... MEXICO CITY, Aug. 5 In a new ... on global leaders to aggressively,expand HIV prevention programs aimed ... Citing hundreds of clinical trials and,observational studies, the report ...
... Sales increase 107% over Second Quarter 2007, EMERYVILLE, ... ) today reported its financial results,for the three and ... income,of $4.5 million, or $0.08 per diluted share, for ... of $10.8 million, or $0.22 per diluted share, in ...
... - Product Revenue Increased 81 Percent; Tests Delivered Grew 69 Percent ... Year over Year - ... - Company Updates 2008 ... Call Today at 4:30 p.m. ET -, REDWOOD CITY, Calif., Aug. 5 Genomic Health,Inc. (Nasdaq: ...
Cached Biology Technology:Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 2Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 3Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 9Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress 10
(Date:8/28/2014)... Protected areas conserve biodiversity and more action is needed ... areas, researchers say. , Published in PLOS ONE ... University of Exeter, used meta-analysis - combining results from ... years of research into these areas, to determine whether ... School of Biological Sciences, said protecting an area from ...
(Date:8/28/2014)... Many of the world,s most important crop-producing countries will ... the century if current trends continue, according to a ... More than one-in-ten pest types can already be found ... crops. If this spread advances at its current rate, ... countries will be overwhelmed by pests within the next ...
(Date:8/27/2014)... , Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... announced underwritten public offering of units of common stock ... for gross proceeds of $20 million, prior to deducting ... the Company.  The shares and warrants are immediately separable ... unit sold in the offering consists of 2,000 shares ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2New study charts the global invasion of crop pests 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... Spring Harbor, NY A four-year, multi-institutional effort co-led by ... publication of a landmark series of papers in the journal ... of maize ( Zea mays ). Maize, or corn, as ... of the world,s most important plants and the most valuable ...
... at Louisiana Tech University has found that a naturally ... salvinia. Giant salvinia is a noxious and invasive ... bodies of water, altering entire ecosystems. Under ideal ... in size every three days. Dr. H. Lynn ...
... WEST LAFAYETTE, Ind. - Purdue University scientists have helped identify ... wall development in maize, an effort that expands their ability ... biofuels production. The Purdue scientists, led by Nicholas Carpita, ... the 750 cell wall genes in the journal Plant ...
Cached Biology News:Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Microorganism may provide key to combating giant salvinia throughout Louisiana 2Maize cell wall genes identified, giving boost to biofuel research 2
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Biology Products: